← Back to Clinical Trials
Recruiting NCT03117036
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Trial Parameters
Condition Lymphoma, Non-Hodgkin
Sponsor Samsung Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 600
Sex ALL
Min Age 20 Years
Max Age 90 Years
Start Date 2017-03-01
Completion 2026-12-28
All Conditions
Interventions
Chemotherapy
Brief Summary
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Eligibility Criteria
Inclusion Criteria: 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent Exclusion Criteria: 1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent
Related Trials
NCT06541327
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
View Trial →
NCT06923397
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma
View Trial →
NCT04090268
Precision Exercise in Children With Malignant Hemopathies
View Trial →